Menu Search
Equities

Novakand Pharma AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3EE0:FRA

Novakand Pharma AB

Actions
  • Price (EUR)0.0001
  • Today's Change0.00 / 0.00%
  • Shares traded5.42k
  • 1 Year change-99.87%
  • Beta0.2064
Data delayed at least 15 minutes, as of Feb 06 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Novakand Pharma AB (publ), formerly Kancera AB is a Sweden-based company engaged in the biotechnology industry, that develops and sells drug candidates in the field of cancer. The Company focuses on the development of small molecule drug candidates targeting immune cell modulation for the treatment of cardiovascular diseases and cancer. Their key product candidates are KAND567 and KAND145, which are clinical-stage pharmaceutical compounds. These compounds act through the fractalkine system, a biological pathway involved in regulating immune and cancer cell activity. The primary goal of these drug candidates is to reduce inflammation and tissue damage in conditions such as ST-elevation myocardial infarction (STEMI) and ovarian cancer.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-51.90m
  • Incorporated2010
  • Employees5.00
  • Location
    Novakand Pharma ABNanna Svartz Vag 4SOLNA 171 65SwedenSWE
  • Phone+46 850126080
  • Websitehttps://novakand.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVKAN:STO since
announced		Transaction
value
SVF Vaccines ABAnnounced22 Dec 202522 Dec 2025Announced-13.33%2.79m
Data delayed at least 15 minutes, as of Feb 06 2026 17:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.